CGS-CIMB sees decent earnings growth for Pharmaniaga, reiterates ‘add’ call

KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd is positive on Pharmaniaga Bhd on the expectation of a decent financial year 2023-2024 earnings growth for the company.

“The ample excess production capacity at Pharmaniaga’s existing plants will allow it to ramp up output in the next three to five years — in light of rising pharmaceutical demand and new product launches — with little to no incremental capital expenditure, thus potentially leading to better economies of scale and margins,” it said.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

V S Industry’s counter measures prove effectivePETALING JAYA: V S Industry Bhd is projected to sustain a positive outlook on revenue growth despite rising cost pressures and labour shortages, which had caused a decline in its operating efficiency.
La source: staronline - 🏆 4. / 75 Lire la suite »